Holen Sie sich die Stockscreener-App
56.52
2.87%
1.595
Schlusskurs vom Vortag:
$54.93
Offen:
$55.44
24-Stunden-Volumen:
296.85K
Relative Volume:
0.36
Marktkapitalisierung:
$2.63B
Einnahmen:
$1.32B
Nettoeinkommen (Verlust:
$175.44M
KGV:
15.53
EPS:
3.6395
Netto-Cashflow:
$308.08M
1W Leistung:
-0.27%
1M Leistung:
-10.76%
6M Leistung:
+15.93%
1J Leistung:
-11.09%
1-Tages-Spanne:
$54.84
$57.11
1-Wochen-Bereich:
$53.88
$57.72
52-Wochen-Spanne:
$47.31
$87.32
Haemonetics Corp Stock (HAE) Company Profile
Firmenname
Haemonetics Corp
Sektor
Branche
Telefon
(781) 848-7100
Adresse
125 SUMMER STREET, BOSTON, MA
Compare HAE vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HAE
Haemonetics Corp
|
56.52 | 2.55B | 1.32B | 175.44M | 308.08M | 3.6395 |
ABT
Abbott Laboratories
|
102.60 | 177.03B | 44.33B | 6.50B | 7.40B | 3.717 |
SYK
Stryker Corp
|
328.25 | 124.89B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
86.75 | 110.08B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
62.40 | 93.53B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
80.09 | 45.84B | 6.07B | 1.06B | 1.34B | 1.8063 |
Haemonetics Corp Stock (HAE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-15 | Herabstufung | Needham | Buy → Hold |
| 2025-12-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-08-11 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2025-08-08 | Bestätigt | Barrington Research | Outperform |
| 2025-08-08 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-07-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-06-26 | Eingeleitet | Robert W. Baird | Outperform |
| 2025-02-07 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2024-12-06 | Eingeleitet | JP Morgan | Overweight |
| 2024-11-08 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-09-13 | Eingeleitet | CL King | Buy |
| 2024-09-11 | Eingeleitet | BofA Securities | Neutral |
| 2024-09-10 | Eingeleitet | BTIG Research | Buy |
| 2024-06-12 | Hochstufung | Needham | Hold → Buy |
| 2022-10-13 | Eingeleitet | Mizuho | Buy |
| 2022-01-27 | Herabstufung | Needham | Buy → Hold |
| 2021-12-15 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-08-17 | Fortgesetzt | Raymond James | Outperform |
| 2021-06-17 | Eingeleitet | Citigroup | Buy |
| 2021-05-14 | Hochstufung | CJS Securities | Market Perform → Market Outperform |
| 2021-04-20 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-19 | Herabstufung | CJS Securities | Market Outperform → Market Perform |
| 2021-02-03 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
| 2021-01-21 | Herabstufung | Barrington Research | Outperform → Mkt Perform |
| 2020-11-05 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
| 2020-05-06 | Herabstufung | Barrington Research | Outperform → Mkt Perform |
| 2020-03-31 | Hochstufung | CJS Securities | Market Perform → Market Outperform |
| 2020-01-10 | Eingeleitet | Needham | Buy |
| 2019-08-07 | Bestätigt | Barrington Research | Outperform |
| 2019-05-14 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2019-05-08 | Bestätigt | Barrington Research | Outperform |
| 2018-08-09 | Bestätigt | Barrington Research | Outperform |
| 2018-02-07 | Bestätigt | Barrington Research | Outperform |
| 2018-01-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2017-11-08 | Bestätigt | Barrington Research | Outperform |
| 2017-08-08 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
| 2017-07-13 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2017-02-07 | Herabstufung | Barrington Research | Outperform → Mkt Perform |
| 2016-11-08 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
| 2016-11-07 | Bestätigt | The Benchmark Company | Hold |
| 2016-09-20 | Herabstufung | CJS Securities | Market Outperform → Market Perform |
| 2016-08-15 | Herabstufung | Sidoti | Buy → Neutral |
| 2016-08-02 | Bestätigt | Jefferies | Buy |
| 2016-08-02 | Bestätigt | The Benchmark Company | Hold |
Alle ansehen
Haemonetics Corp Aktie (HAE) Neueste Nachrichten
Automatic Blood Bag Tube Stripper Market Is Going to Boom | Terumo - openPR.com
Haemonetics: FDA Label Expansion and New Product Launches Poised to Reignite Vascular Closure Growth by FY27 - TipRanks
FDA Expands Approval for Haemonetics' (HAE) VASCADE MVP XL Syste - GuruFocus
Is Haemonetics (HAE) Leveraging VASCADE MVP XL’s FDA Expansion To Deepen Its EP Moat? - simplywall.st
Haemonetics wins FDA nod for expanded vascular closure system use - Investing.com
Haemonetics Wins FDA Approval to Expand Label for VASCADE MVP XL - marketscreener.com
FDA expands use of Haemonetics device in atrial fibrillation care - Stock Titan
Haemonetics Corp. Experiences Revision in Stock Evaluation Amid Market Challenges - Markets Mojo
Haemonetics stock maintained at Buy by BTIG on FDA label expansion - Investing.com South Africa
Assenagon Asset Management S.A. Sells 99,083 Shares of Haemonetics Corporation $HAE - MarketBeat
Short Interest in Haemonetics Corporation (NYSE:HAE) Decreases By 29.7% - MarketBeat
Vanguard disaggregates holdings after internal realignment (NYSE: HAE) - Stock Titan
Update Recap: What drives Haemonetics Corporations stock price2026 Breakouts & Risk Controlled Stock Pick Alerts - baoquankhu1.vn
Q2 EPS Estimates for Haemonetics Boosted by Zacks Research - MarketBeat
A Look At Haemonetics (HAE) Valuation After Recent Share Price Weakness - simplywall.st
Q3 EPS Estimates for Haemonetics Increased by Zacks Research - MarketBeat
HAE Price Today: Haemonetics Corporation Stock Price, Quote & Chart - mexc.co
Haemonetics Corp stock faces uncertainty amid lack of fresh catalysts in blood management sector - AD HOC NEWS
Why Haemonetics Stock Is Suddenly Bouncing Back - TipRanks
Hospital Solutions launch from Haemonetics aims to transform patient care standards - Traders Union
Haemonetics Corp Stock Surges on Strong Momentum Amid Plasma and Hemostasis Demand - AD HOC NEWS
Don't Get Too Worked Up Over Haemonetics's Earnings - Yahoo
What Investors Should Know About a $24 Million Exit From a Medical Device Stock Down 9% This Past Year - AOL.com
Haemonetics Corp. Forms Death Cross, Signaling Potential Bearish Trend Ahead - Markets Mojo
HAE Stock Price, Quote & Chart | HAEMONETICS CORP/MASS (NYSE:HAE) - ChartMill
Here's Why Haemonetics (HAE) is a Strong Value Stock - Yahoo Finance
Haemonetics Corporation (HAE) Q3 performance prompts Baird model update, price target falls to $81 - MSN
London Co. of Virginia Decreases Stake in Haemonetics Corporation $HAE - MarketBeat
Haemonetics Corporation (HAE) Stock Price Prediction for 2026, 2030-2040 - Traders Union
Why Haemonetics (HAE) is a Top Momentum Stock for the Long-Term - Yahoo Finance
Haemonetics Corporation $HAE Shares Purchased by Invenomic Capital Management LP - MarketBeat
Haemonetics Corp Stock (ISIN: US4041191090) Faces Pressure Amid Hospital Recovery and Debt Concerns - AD HOC NEWS
Haemonetics Corporation (NYSE:HAE) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Is Haemonetics (HAE) Quietly Rewiring Its Margin Profile Through NexSys PCS And Hospital Acquisitions? - simplywall.st
Does Haemonetics' (HAE) Hospital Rebound and NexSys Expansion Reframe Its Competitive Positioning? - Yahoo Finance
Aristotle Capital Boston LLC Increases Stock Position in Haemonetics Corporation $HAE - MarketBeat
Citi Maintains Haemonetics(HAE.US) With Hold Rating, Cuts Target Price to $70 - 富途牛牛
Haemonetics Corp Stock (ISIN: US4041191090) Expands Hospital Portfolio Amid Valuation Discount and A - AD HOC NEWS
Citi Maintains Haemonetics(HAE.US) With Hold Rating, Maintains Target Price $70 - 富途牛牛
Haemonetics Expands Hospital Portfolio As Investors Weigh Growth And Valuation - simplywall.st
Haemonetics Corp. Experiences Revision in Its Stock Evaluation Amid Market Dynamics - Markets Mojo
Haemonetics Corporation $HAE Shares Sold by Schroder Investment Management Group - MarketBeat
Is it Apt to Retain Haemonetics Stock in Your Portfolio for Now? - Yahoo Finance
Haemonetics Corporation $HAE Shares Acquired by Barrow Hanley Mewhinney & Strauss LLC - MarketBeat
Haemonetics price target lowered to $70 from $75 at Citi - TipRanks
Citigroup Maintains Neutral Rating on Haemonetics (HAE), Lowers Price Target | HAE Stock News - GuruFocus
Citigroup Issues Pessimistic Forecast for Haemonetics (NYSE:HAE) Stock Price - MarketBeat
Haemonetics launches recruitment drive to expand clinical support roles - Traders Union
HAE SEC FilingsHaemonetics Corp Mass 10-K, 10-Q, 8-K Forms - Stock Titan
Assessing Haemonetics (HAE) Valuation After Recent Share Price Pullback - Yahoo Finance
A Look Back at Medical Devices & SuppliesSpecialty Stocks’ Q4 Earnings: Haemonetics (NYSE:HAE) Vs The Rest Of The Pack - Yahoo Finance
Finanzdaten der Haemonetics Corp-Aktie (HAE)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.00%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):